Evidence map›Paper›PMID 33674951›Full record

ArticleInternational urology and nephrology2021

Mutual effect modification between adiponectin and HDL as risk factors of cardiovascular events in Type 2 diabetes individuals: a cohort study.

Stefanos Roumeliotis, Vassilios Liakopoulos, Athanasios Roumeliotis, Aikaterini Stamou, Stylianos Panagoutsos, Graziella D'Arrigo, Giovanni Tripepi

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Stefanos RoumeliotisDivision of Nephrology and Hypertension, First Department of Internal Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636, Thessaloniki, Greece.
Vassilios LiakopoulosDivision of Nephrology and Hypertension, First Department of Internal Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636, Thessaloniki, Greece. liakopul@otenet.gr.ORCID http://orcid.org/0000-0002-7564-2724
Athanasios RoumeliotisDivision of Nephrology and Hypertension, First Department of Internal Medicine, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636, Thessaloniki, Greece.
Aikaterini StamouDepartment of Microbiology, AHEPA Hospital, School of Medicine, Aristotle University of Thessaloniki, 54636, Thessaloniki, Greece.
Stylianos PanagoutsosDepartment of Nephrology, School of Medicine, Democritus University of Thrace, 68100, Alexandroupolis, Greece.
Graziella D'ArrigoInstitute of Clinical Physiology (IFC-CNR), Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria, 89127, Reggio Calabria, Italy.
Giovanni TripepiInstitute of Clinical Physiology (IFC-CNR), Clinical Epidemiology and Physiopathology of Renal Diseases and Hypertension of Reggio Calabria, 89127, Reggio Calabria, Italy.
Aristotle University of Thessaloniki · GRIstituto di Fisiologia Clinica · ITDemocritus University of Thrace · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to assess whether high-density lipoprotein (HDL) cholesterol modifies the association between adiponectin and incident cardiovascular (CV) morbidity and mortality in Type 2 Diabetes Mellitus (T2DM) and vice versa.

methodsAt baseline, 106 T2DM participants with various degrees of renal function were enrolled and followed up over a period of 7 years with fatal/nonfatal CV events as outcome.

resultsDuring the follow-up, 49 participants experienced incident CV events (28 fatal, 21 nonfatal). On univariate Fine and Gray sub-hazard models, HDL cholesterol was a strong modifier of the association between adiponectin and CV outcomes both on crude (P = 0.011) and gender- and eGFR-adjusted models (P = 0.010). The protective effect for CV events portended by a fixed increase in adiponectin (1 μg/ml) was progressively higher across increasing values of HDL cholesterol. Moreover, plasma adiponectin also modified the protective effect of HDL on CV outcomes both in crude and multivariate analyses. We found a mutual effect modification between adiponectin and HDL as risk factors of CV events in participants with T2DM.

conclusionOur results are coherent with the hypothesis that HDL cholesterol might play a pivotal role in the interpretation of the association between adiponectin and the risk of adverse CV outcomes in this population.

Indexed as

Effect Modifier, EpidemiologicAdiponectinAgedAged, 80 and overCardiovascular DiseasesCholesterol, HDLDiabetes Mellitus, Type 2FemaleHumansIncidenceKidney Function TestsMaleMiddle AgedRisk FactorsAdiponectinCholesterol, HDLAdiponectinCardiovascular diseaseDiabetic chronic kidney diseaseEffect modificationHigh-density lipoprotein

Identifiers

PMID33674951
OpenAlexW3134770510

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.